Opinion & analysis

The Blockbusters No One Talks About

Although their patent protection has expired, big-name blockbusters continue to produce huge revenues for the pharmaceutical companies that produce them. Take a look at how some well-known drugs may no longer be making headlines, but continue to be big earners.

The Blockbusters No One Talks About

Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology

Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry

Eight Things To Know From Novartis’ Third Quarter Call

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement

Takeda To Press On With Core R&D Strategy Post-Shire

European Commission Sheds Light On MDR/IVDR Progress In Vital Update

What Should You Be Earning? Salary Benchmarks And Hiring Trends In Regulatory Affairs

Two EU Notified Body Frontrunners In Race For Designation Under New Regulations

CMS Actively Looking For New Reimbursement Pathway For Innovative Devices

Investigator Horror Stories 3: Boozing On The Job? Yup, That Happened – As Have These Other Shocking Tales Of Irregular FDA Inspections

Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

The Emergence Of IO

As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability